Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Claudio Sette

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2864-8266; OpenAlex author ID A5020418933. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
46
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 15

  1. Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment. Co-author DOI 10.1002/pro.70444↗
  2. U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity Last author DOI 10.1186/s13046-026-03795-3↗
  3. Increased cytotoxic effects via combined treatment of magnetic field and radiation therapy in patient-derived organoids of pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-9009316/v1↗
  4. Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer Co-author DOI 10.34133/cancomm.0030↗
  5. Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer. Last author DOI 10.1016/j.molmed.2024.11.007↗
  6. DDX21 Controls Cell Cycle Progression and Autophagy in Pancreatic Cancer Cells. Last author DOI 10.3390/cancers17040570↗
  7. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Last author DOI 10.1016/j.xcrm.2024.101411↗
  8. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/1878-0261.12847↗
  9. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… Co-author DOI 10.1136/jitc-2021-002876↗
  10. RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
  11. Drug resistance in pancreatic cancer: New player caught in act. First author DOI 10.1016/j.ebiom.2019.02.008↗
  12. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. Co-author DOI 10.3892/or.2018.6233↗
  13. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. Last author DOI 10.1038/cddis.2017.562↗
  14. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Last author DOI 10.1038/onc.2015.270↗
  15. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Last author DOI 10.1038/onc.2012.306↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Veronica Ruta · 6 shared papers, 2020–2026 · strength 1.50
  2. Valentina Panzeri · 8 shared papers, 2017–2026 · strength 1.36
  3. Gabriele Capurso · 8 shared papers, 2013–2024 · strength 0.85
  4. Giampaolo Tortora · 4 shared papers, 2021–2026 · strength 0.74
  5. Chiara Naro · 3 shared papers, 2021–2025 · strength 0.71
  6. Carmine Carbone · 3 shared papers, 2021–2026 · strength 0.50
  7. Adriana Leccese · 2 shared papers, 2024–2025 · strength 0.45
  8. Giuseppe Quero · 2 shared papers, 2024–2026 · strength 0.41
  9. Vincenzo Corbo · 2 shared papers, 2021–2026 · strength 0.34
  10. Antonio Agostini · 2 shared papers, 2021–2026 · strength 0.34
  11. Francesco De Sanctis · 2 shared papers, 2021–2026 · strength 0.34
  12. Geny Piro · 2 shared papers, 2021–2026 · strength 0.34
  13. Annalisa Pia Abbinantefina · 1 shared paper, 2026 · strength 0.28
  14. Gianni Colotti · 1 shared paper, 2026 · strength 0.28
  15. Gianfranco Delle Fave · 4 shared papers, 2013–2018 · strength 0.27
  16. Claudio Doglioni · 2 shared papers, 2020–2024 · strength 0.26
  17. Lívia Archibugi · 2 shared papers, 2020–2024 · strength 0.26
  18. Massimo Falconi · 2 shared papers, 2020–2024 · strength 0.26
  19. Paolo Giorgio Arcidiacono · 2 shared papers, 2020–2024 · strength 0.26
  20. Juan Carlos López-Gil · 1 shared paper, 2026 · strength 0.25
  21. Ana Galván-del-Rey · 1 shared paper, 2026 · strength 0.25
  22. Carmen E. Guerra · 1 shared paper, 2026 · strength 0.25
  23. Ilaria Passacantilli · 3 shared papers, 2016–2018 · strength 0.23
  24. Alessia Caggiano · 1 shared paper, 2026 · strength 0.23
  25. Maria Antonietta Gambacorta · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.